Trials / Recruiting
RecruitingNCT06122584
Diagnostic Performance of [18F]PSMA-1007 PET/CT Imaging in Patients With Newly-Diagnosed Prostate Cancer
Prospective, Multi-Center Study to Assess the Diagnostic Performance of [18F]PSMA-1007 PET/CT Imaging in Patients With Newly-Diagnosed High-Risk or Very-High-Risk Prostate Cancer
- Status
- Recruiting
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 380 (estimated)
- Sponsor
- ABX advanced biochemical compounds GmbH · Industry
- Sex
- Male
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study assess the Diagnostic Performance of \[18F\]PSMA-1007 PET/CT Imaging in Patients with Newly-Diagnosed High-Risk or Very-High-Risk Prostate Cancer
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | [18F]PSMA-1007 | Diagnostic radiopharmaceutical for PET scan |
Timeline
- Start date
- 2024-06-13
- Primary completion
- 2027-03-01
- Completion
- 2027-09-01
- First posted
- 2023-11-08
- Last updated
- 2026-04-14
Locations
18 sites across 6 countries: France, Germany, Italy, Japan, Netherlands, Spain
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06122584. Inclusion in this directory is not an endorsement.